Literature DB >> 1953131

Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections.

M Pomerantz1, L Madsen, M Goble, M Iseman.   

Abstract

Between August 1983 and October 1990, 42 patients with resistant Mycobacterium tuberculosis underwent 44 pulmonary resections. During the same time, 38 patients with mycobacterial infections other than tuberculosis had 41 pulmonary resections. All patients either were poor candidates for medical therapy alone or had existing complications requiring surgical intervention. There was one operative death in each group, both from adult respiratory distress syndrome (postpneumonectomy pulmonary edema). Complications were high, with bronchopleural fistula most commonly occurring after right pneumonectomy in patients infected with Mycobacterium avium with superimposed infection with nonmycobacterial pathogens. In patients undergoing pneumonectomy for resistant Mycobacterium tuberculosis, the left lung was most often resected. It is recommended that if localized disease is present and medical treatment is likely to fail, pulmonary resection should be performed for resistant Mycobacterium tuberculosis infection after 3 months of drug-specific therapy. Muscle flaps were used frequently to avoid residual space and bronchial stump problems. Earlier resection in patients with indolent nontuberculous mycobacterial pulmonary infections is advocated before extensive polymicrobial contamination and right lung destruction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1953131     DOI: 10.1016/0003-4975(91)91289-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  18 in total

1.  Surgical management of multidrug-resistant tuberculosis.

Authors:  S Sasano; H Yamamoto; T Otsuka; A Fujita; T Onuki; S Nitta
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-02

Review 2.  Surgery and pleuro-pulmonary tuberculosis: a scientific literature review.

Authors:  Dragan Subotic; Piotr Yablonskiy; Giorgia Sulis; Ioan Cordos; Danail Petrov; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  The medical and surgical treatment of drug-resistant tuberculosis.

Authors:  Gregory L Calligaro; Loven Moodley; Greg Symons; Keertan Dheda
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

4.  Outcomes after pneumonectomy for benign disease: the impact of urgent resection.

Authors:  Jacob Klapper; Sameer Hirji; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark W Onaitis; Mark F Berry
Journal:  J Am Coll Surg       Date:  2014-04-08       Impact factor: 6.113

5.  HRCT in detection of pulmonary infections from nontuberculous mycobacteria: personal experience.

Authors:  I Ferrara; S Cappabianca; L Brunese; T Valente; E Muto; R Muto; A Rotondo
Journal:  Radiol Med       Date:  2009-03-11       Impact factor: 3.469

Review 6.  Surgical treatment of nontuberculous mycobacterial lung disease.

Authors:  Yuji Shiraishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-04-17

Review 7.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 8.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

9.  Early and Long-term Outcomes of Pneumonectomy for Treating Sequelae of Pulmonary Tuberculosis.

Authors:  Chun Sung Byun; Kyung Young Chung; Kyoung Sik Narm; Jin Gu Lee; Daejin Hong; Chang Young Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-04-03

10.  The outcomes of anatomical lung resection for nontuberculous mycobacterial lung disease.

Authors:  Tadashi Sakane; Katsunari Matsuoka; Sakiko Kumata; Risa Watanabe; Tetsu Yamada; Takahisa Matsuoka; Shinjiro Nagai; Mitsuhiro Ueda; Yoshihiro Miyamoto
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.